Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tenax Therapeutics (TENX) EBITDA (2016 - 2026)

Tenax Therapeutics' EBITDA history spans 8 years, with the latest figure at $1.4 million for Q4 2017.

  • On a quarterly basis, EBITDA fell 95.44% to $1.4 million in Q4 2017 year-over-year; TTM through Dec 2017 was $8.8 million, a 79.83% decrease, with the full-year FY2025 number at -$56.4 million, down 189.24% from a year prior.
  • EBITDA hit $1.4 million in Q4 2017 for Tenax Therapeutics, up from $1.2 million in the prior quarter.
  • Over the last five years, EBITDA for TENX hit a ceiling of $29.7 million in Q4 2016 and a floor of -$1.6 million in Q1 2013.
  • Historically, EBITDA has averaged $4.9 million across 5 years, with a median of $3.4 million in 2013.
  • Biggest five-year swings in EBITDA: surged 940.37% in 2014 and later tumbled 95.44% in 2017.
  • Tracing TENX's EBITDA over 5 years: stood at $3.5 million in 2013, then increased by 14.16% to $4.0 million in 2014, then skyrocketed by 153.59% to $10.2 million in 2015, then soared by 190.64% to $29.7 million in 2016, then crashed by 95.44% to $1.4 million in 2017.
  • Business Quant data shows EBITDA for TENX at $1.4 million in Q4 2017, $1.2 million in Q3 2017, and $3.0 million in Q2 2017.